Back to Agenda
[S28] Global Oncology Development - Be a Game Changer in Oncology Development -
Session Chair(s)
Hironobu Saito, PHD
Corporate Advisor, Daiichi Sankyo Co., Ltd., Japan
The world surrounding cancer treatment continues to evolve rapidly. New, emerging products include not only immuno-oncology drugs, but also regenerative medicine and medical devices, that expand the therapeutic choice in the field of cancer treatment. Thanks to the rapidly evlolving digital applications, artificial intelligence (AI), and the Internet of Things (IoT) that affect clinical trial operations, clinical development faces both challenge and opportunity to keep the evaluation of novel therapeutic products simple and reliable. This session provides a great opportunity to discuss how we can move towards ideal future direction of global clinical trial in oncology. This is a pre-session for DIA Global Oncology Development 2020 held on Jan 31, 2020.
Speaker(s)
Opportunities for More Contribution to Clinical Trials
Executive Vice President Data Business, CMIC Co., Ltd, Japan
Site Capability for Global Study - from Both “ Sites and Sponsors” Perspectives
Oncology Medical Science Department, Medical Affairs Division, Daiichi Sankyo Co., Ltd., Japan
Have an account?